BrightPath Biotherapeutics Overview
- Year Founded
-
2003

- Status
-
Public
- Employees
-
28

- Stock Symbol
-
4594

- Share Price
-
$0.28
- (As of Friday Closing)
BrightPath Biotherapeutics General Information
Description
BrightPath Biotherapeutics Co Ltd is a biopharmaceutical venture company. It is engaged in developing novel cancer immunotherapeutics. Its products include two candidate products: ITK-1 and GRN-1201 which are in the clinical trial stage.
Contact Information
Website
www.brightpathbio.comCorporate Office
- Fukuoka Bio Incubation Center, 1-1 Hyakunenkoen
- Kurume-shi
- Fukuoka, 839-0864
- Japan
Corporate Office
- Fukuoka Bio Incubation Center, 1-1 Hyakunenkoen
- Kurume-shi
- Fukuoka, 839-0864
- Japan
BrightPath Biotherapeutics Stock Performance
As of 16-May-2025, BrightPath Biotherapeutics’s stock price is $0.28. Its current market cap is $24.8M with 88.1M shares.
(As of Friday Closing)
Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
---|---|---|---|---|---|---|
$0.28 | $0.27 | $0.22 - $0.55 | $24.8M | 88.1M | 1.24M | -$0.11 |
BrightPath Biotherapeutics Financials Summary
As of 30-Sep-2024, BrightPath Biotherapeutics has a trailing 12-month revenue of $558.89.
In Thousands, USD |
TTM 30-Sep-2024 | FY 2024 31-Mar-2024 | FY 2023 31-Mar-2023 | FY 2022 31-Mar-2022 |
---|---|---|---|---|
EV | 19,162 | 22,839 | 67,625 | 23,499 |
Revenue | 1 | 1 | 39 | 137 |
EBITDA | (7,656) | (8,068) | (10,836) | (12,874) |
Net Income | (7,671) | (8,084) | (10,974) | (13,211) |
Total Assets | 11,877 | 8,129 | 12,769 | 22,706 |
Total Debt | 2,276 | 743 | 0 | 717 |
BrightPath Biotherapeutics Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
BrightPath Biotherapeutics Patents
BrightPath Biotherapeutics Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
JP-2024012879-A | Method for producing tumor-reactive t-cell | Pending | 19-Jul-2022 | ||
EP-4506368-A1 | Bispecific antibody to human tim-3 and human cd39, and applications thereof | Pending | 07-Apr-2022 | ||
EP-4506457-A1 | Anti-cd39 antibody | Pending | 25-Mar-2022 | ||
JP-2024149926-A | Cancer peptide vaccine cocktail formulation and method for producing the same | Pending | 06-Aug-2021 | ||
US-20240391997-A1 | Anti-tim-3 antigen antibody or antibody derivative, and use thereof | Pending | 16-Jul-2021 | C07K16/28 |
BrightPath Biotherapeutics Signals
BrightPath Biotherapeutics ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile

Pharmaceuticals
Industry
Rank
Percentile

Biotechnology
Subindustry
Rank
Percentile

BrightPath Biotherapeutics FAQs
-
When was BrightPath Biotherapeutics founded?
BrightPath Biotherapeutics was founded in 2003.
-
Where is BrightPath Biotherapeutics headquartered?
BrightPath Biotherapeutics is headquartered in Fukuoka, Japan.
-
What is the size of BrightPath Biotherapeutics?
BrightPath Biotherapeutics has 28 total employees.
-
What industry is BrightPath Biotherapeutics in?
BrightPath Biotherapeutics’s primary industry is Drug Discovery.
-
Is BrightPath Biotherapeutics a private or public company?
BrightPath Biotherapeutics is a Public company.
-
What is BrightPath Biotherapeutics’s stock symbol?
The ticker symbol for BrightPath Biotherapeutics is 4594.
-
What is the current stock price of BrightPath Biotherapeutics?
As of 16-May-2025 the stock price of BrightPath Biotherapeutics is $0.28.
-
What is the current market cap of BrightPath Biotherapeutics?
The current market capitalization of BrightPath Biotherapeutics is $24.8M.
-
What is BrightPath Biotherapeutics’s current revenue?
The trailing twelve month revenue for BrightPath Biotherapeutics is $558.89.
-
What is BrightPath Biotherapeutics’s annual earnings per share (EPS)?
BrightPath Biotherapeutics’s EPS for 12 months was -$0.11.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »